Crinetics Pharmaceuticals Statistics
Total Valuation
CRNX has a market cap or net worth of $8.81 billion. The enterprise value is $7.56 billion.
| Market Cap | 8.81B |
| Enterprise Value | 7.56B |
Important Dates
The next confirmed earnings date is Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CRNX has 105.44 million shares outstanding. The number of shares has increased by 12.58% in one year.
| Current Share Class | 105.44M |
| Shares Outstanding | 105.44M |
| Shares Change (YoY) | +12.58% |
| Shares Change (QoQ) | +9.47% |
| Owned by Insiders (%) | 1.48% |
| Owned by Institutions (%) | 110.34% |
| Float | 95.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 487.43 |
| Forward PS | 102.97 |
| PB Ratio | 3.46 |
| P/TBV Ratio | 6.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 418.62 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.60, with a Debt / Equity ratio of 0.04.
| Current Ratio | 18.60 |
| Quick Ratio | 18.25 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.17% and return on invested capital (ROIC) is -25.91%.
| Return on Equity (ROE) | -39.17% |
| Return on Assets (ROA) | -24.69% |
| Return on Invested Capital (ROIC) | -25.91% |
| Return on Capital Employed (ROCE) | -41.03% |
| Weighted Average Cost of Capital (WACC) | 5.50% |
| Revenue Per Employee | $30,419 |
| Profits Per Employee | -$835,670 |
| Employee Count | 594 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CRNX has paid $180,000 in taxes.
| Income Tax | 180,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +180.30% in the last 52 weeks. The beta is 0.23, so CRNX's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +180.30% |
| 50-Day Moving Average | 37.75 |
| 200-Day Moving Average | 42.13 |
| Relative Strength Index (RSI) | 93.29 |
| Average Volume (20 Days) | 5,405,406 |
Short Selling Information
The latest short interest is 12.86 million, so 12.19% of the outstanding shares have been sold short.
| Short Interest | 12.86M |
| Short Previous Month | 12.64M |
| Short % of Shares Out | 12.19% |
| Short % of Float | 13.46% |
| Short Ratio (days to cover) | 13.44 |
Income Statement
In the last 12 months, CRNX had revenue of $18.07 million and -$496.39 million in losses. Loss per share was -$5.13.
| Revenue | 18.07M |
| Gross Profit | -339.11M |
| Operating Income | -545.74M |
| Pretax Income | -496.21M |
| Net Income | -496.39M |
| EBITDA | -541.62M |
| EBIT | -545.74M |
| Loss Per Share | -$5.13 |
Balance Sheet
The company has $1.29 billion in cash and $47.86 million in debt, with a net cash position of $1.24 billion or $11.79 per share.
| Cash & Cash Equivalents | 1.29B |
| Total Debt | 47.86M |
| Net Cash | 1.24B |
| Net Cash Per Share | $11.79 |
| Equity (Book Value) | 1.28B |
| Book Value Per Share | 12.16 |
| Working Capital | 1.25B |
Cash Flow
In the last 12 months, operating cash flow was -$414.17 million and capital expenditures -$5.34 million, giving a free cash flow of -$419.52 million.
| Operating Cash Flow | -414.17M |
| Capital Expenditures | -5.34M |
| Depreciation & Amortization | 4.13M |
| Net Borrowing | n/a |
| Free Cash Flow | -419.52M |
| FCF Per Share | -$3.98 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,020.32% |
| Pretax Margin | -2,746.18% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.58% |
| Shareholder Yield | -12.58% |
| Earnings Yield | -5.64% |
| FCF Yield | -4.76% |
Analyst Forecast
The average price target for CRNX is $84.82, which is 1.54% higher than the current price. The consensus rating is "Buy".
| Price Target | $84.82 |
| Price Target Difference | 1.54% |
| Analyst Consensus | Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | 278.70% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CRNX has an Altman Z-Score of 16.5 and a Piotroski F-Score of 3.
| Altman Z-Score | 16.5 |
| Piotroski F-Score | 3 |